FDA-cleared profile

ANDI 2.2

Imeka Solutions, Inc. · MRI · FDA-cleared (510(k))

Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.

Clinical role
Adjunctive brain-MR processing, atlas visualization, segmentation and volumetric reporting.
Images and patients
MRI · Brain
Key limitation
Keep in mind: ANDI does not provide prediction, diagnosis or interpretation of brain health. Outputs are adjunctive and require trained-professional interpretation.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: DICOM diffusion-weighted and T1 brain MR images.
  • Who uses it?Intended users: Trained medical professionals.
  • What does the software produce?Output: DICOM-readable atlas visualization, brain-structure segmentation and volumetric quantification information, including normative or longitudinal comparison when used as described in the summary.
  • What is its most important limitation?Key limitation: ANDI does not provide prediction, diagnosis or interpretation of brain health. Outputs are adjunctive and require trained-professional interpretation.

Clinical takeaway. Clinical role: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.

Evidence takeaway. Evidence from the reviewed source record: K261405 is a modification expanding the normative dataset age range. Its reviewed FDA evidence does not include a new clinical study or diagnostic-performance endpoint.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
  • Exact FDA submission
  • Checked 2026-09-06
Workflow role
Adjunctive brain-MR processing, atlas visualization, segmentation and volumetric reporting.
  • Exact FDA submission
  • Checked 2026-09-06
Required input
DICOM diffusion-weighted and T1 brain MR images.
  • Exact FDA submission
  • Checked 2026-09-06
Output and clinician action
DICOM-readable atlas visualization, brain-structure segmentation and volumetric quantification information, including normative or longitudinal comparison when used as described in the summary.
  • Exact FDA submission
  • Checked 2026-09-06
Care setting
The K261405 modification expands the normative-dataset lower age boundary to 16-17 years; the reviewed summary does not establish a broader care-setting restriction.
  • Exact FDA submission
  • Checked 2026-09-06
Intended users
Trained medical professionals.
  • Exact FDA submission
  • Checked 2026-09-06
Limitations
ANDI does not provide prediction, diagnosis or interpretation of brain health. Outputs are adjunctive and require trained-professional interpretation.
  • Exact FDA submission
  • Checked 2026-09-06
Evidence summary
K261405 is a modification expanding the normative dataset age range. Its reviewed FDA evidence does not include a new clinical study or diagnostic-performance endpoint.
  • Exact FDA submission
  • Checked 2026-09-06

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K261405 is a modification expanding the normative dataset age range. Its reviewed FDA evidence does not include a new clinical study or diagnostic-performance endpoint.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-06

No diagnostic sensitivity endpoint was established by the reviewed modification summary.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-06

No diagnostic specificity endpoint was established by the reviewed modification summary.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM diffusion-weighted and T1 brain MR images.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-06 · FDA 510(k) K261405: ANDI 2.2

  2. Routing

    Source context, not route validation: Processes and outputs DICOM data; exact PACS, EHR and deployment interfaces were not established beyond the summary.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-06 · FDA 510(k) K261405: ANDI 2.2

  3. AI processing

    Source context, not route validation: Software as a medical device that may be deployed cloud-based or on premises; the FDA summary describes it as SaaS without a graphical user interface.

    Scope: Exact FDA submission. Actual site architecture and cloud region require vendor/site confirmation.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-06 · FDA 510(k) K261405: ANDI 2.2

  4. Returned objects

    Source context, not route validation: DICOM-readable atlas visualization, brain-structure segmentation and volumetric quantification information, including normative or longitudinal comparison when used as described in the summary.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-06 · FDA 510(k) K261405: ANDI 2.2

  5. Viewer/worklist/report

    Unresolved route: DICOM-readable atlas visualization, brain-structure segmentation and volumetric quantification information, including normative or longitudinal comparison when used as described in the summary.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-06 · FDA 510(k) K261405: ANDI 2.2

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Software as a medical device that may be deployed cloud-based or on premises; the FDA summary describes it as SaaS without a graphical user interface.
  • Exact FDA submission
  • Checked 2026-09-06

Actual site architecture and cloud region require vendor/site confirmation.

Integration
Processes and outputs DICOM data; exact PACS, EHR and deployment interfaces were not established beyond the summary.
  • Exact FDA submission
  • Checked 2026-09-06

Current ANDI family context

Imeka's current news page describes ANDI 2.0 as adding brain volumetry to the product family and describes the product as quantitative brain imaging software.

product family · checked 2026-09-06

Current ANDI 2.0 family material does not establish feature parity with the K261405 ANDI 2.2 submission.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K261405
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-05-28
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-06Last searched
22Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored PubMed and ClinicalTrials candidate metadata snapshots were screened; both arrays were empty. No candidate evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision summary, vendor product page, literature index, trial registry, stored candidate metadata, stored recall candidates, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-06 - Exact FDA submission

    No public exact-version price or procurement record reviewed.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Imeka ANDI 2.2 reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Imeka trade press (BioWorld) mentions codes but no vendor or payer page names one for this product. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-06 - Exact FDA submission

    Cloud/on-premise deployment language does not establish formal security controls for an installed configuration.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-06 - Exact FDA submission

    Trained-user intent does not establish a verified current training program.

  • Monitoring: Not verified - checked 2026-09-06 - Exact FDA submission

    No verified monitoring service was found. Site acceptance should test DICOM input/output, processing failures and clinician review workflow.

7 sources - 3 history items

Source ledger

  1. FDA 510(k) K261405: ANDI 2.2

    U.S. Food and Drug Administration - Accessed 2026-09-06

    Scope: identity, clinicalUse, modality, anatomy, implementationCapabilities, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. ANDI 2.2 model card (K261405)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, integration, anatomy, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Imeka news: ANDI 2.0 product-family update

    Imeka - Accessed 2026-09-06

    Scope: productFamily, currentCommercialContext

Research history

  1. K261405 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260032

Morph

BeauBrain Healthcare, Inc.

Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.

Modality
MRI
Anatomy
Brain
Decision
2026-05-13
FDA-cleared K253057

AI-Rad Companion Brain MR

Siemens Healthcare GmbH

Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.

Modality
MRI
Anatomy
Brain
Decision
2026-01-22
FDA-cleared K252298

ANDI 2.0

Imeka Solutions, Inc.

Authorized purpose: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.

Modality
MRI
Anatomy
Brain
Decision
2025-10-22
FDA-cleared K251483

SwiftSight-Brain

AIRS Medical Inc.

Authorized purpose: Adjunctive brain MRI morphometry and lesion-quantification support for qualified healthcare professionals, including segmented overlays, volumetric measurements, normative percentiles and longitudinal comparison.

Modality
MRI
Anatomy
Brain
Decision
2025-09-23

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history